News

Cognyte Shows Strong Growth in Third Quarter FY 2025 Results

Cognyte Shows Strong Growth in Third Quarter FY 2025 Results

Cognyte Reports Third Quarter Fiscal 2025 Financial Results

Cognyte Software Ltd. (NASDAQ: CGNT), a global leader in investigative analytics software, has revealed strong financial results for the third quarter of the fiscal year ending January 31, 2025. The company has showcased remarkable financial progress, demonstrating its ability to navigate a competitive landscape while growing its revenues and enhancing overall profitability.

Financial Summary for Q3 FY 2025

During the third quarter, Cognyte achieved a revenue of $89.0 million, which marks an impressive 12.1% increase compared to the same quarter last year. Additionally, the company reported a GAAP operating loss of $2.2 million, a significant improvement relative to the $2.8 million loss reported in the previous year. Non-GAAP operating income improved to $3.4 million, up from $1.2 million during the corresponding period of last year.

Year-to-Date Performances

For the nine months ending October 31, 2024, Cognyte's total revenue reached $256.1 million, up 11.5% compared to the same period last year. Notably, the GAAP operating loss for this period also decreased to $5.8 million from $15.2 million, illustrating effective cost management and operational efficiency.

Adjusted EBITDA Gains

Adjusted EBITDA for Q3 showed robust growth, climbing 41.9% to $6.6 million from $4.6 million year-over-year. This performance underscores the inherent leverage within Cognyte's financial model and its ability to scale operations efficiently despite market fluctuations.

Management Insights

Elad Sharon, Cognyte’s Chief Executive Officer, shared insights into the company's performance, stating, "This quarter further demonstrated the progress Cognyte has made in executing our business strategy, driving growth initiatives and enhancing profitability. The market for our solutions continues to grow as organizations confront an increasingly complex range of threats. Leveraging cutting-edge AI, Cognyte is uniquely equipped to empower customers to mitigate these challenges and is aligned with our mission to make the world a safer place." He also noted that the company is raising its full-year outlook due to sustained demand and strong market visibility.

Financial Outlook

Based on overwhelming year-to-date performance, Cognyte has updated its projections for the fiscal year ending January 31, 2025. The anticipated revenue is expected to reach approximately $349 million, marking a growth target of 11% compared to the previous year. Adjusted EBITDA is also anticipated to hit around $26 million at the midpoint.

Extended Operational Highlights

Other financial metrics reveal a promising trajectory for the company. As of October 31, 2024, Cognyte reported $107.3 million in cash, cash equivalents, and short-term investments. Furthermore, for the quarter, net cash provided by operating activities amounted to $12.3 million, a delightful contrast to the negative cash flow in the previous year’s comparable period. The company believes this trend will facilitate future investments and strategic initiatives.

Future Directions

Cognyte Software Ltd. continues to explore strategic investments to bolster its market position and enhance its value proposition to customers. The company’s ability to deliver significant insights through its software will empower clients to tackle security threats more effectively.

Frequently Asked Questions

What were Cognyte's total revenues for Q3 FY 2025?

Cognyte reported revenues of $89.0 million for the third quarter of FY 2025.

How did Cognyte's GAAP operating loss for Q3 FY 2025 compare to the prior year?

The GAAP operating loss for Q3 FY 2025 decreased to $2.2 million, compared to a loss of $2.8 million in the same period last year.

What is the outlook for Cognyte's revenue for FY 2025?

The company expects to generate approximately $349 million in revenue for the fiscal year ending January 31, 2025.

What is the significance of the adjusted EBITDA increase reported?

The adjusted EBITDA increase of 41.9% to $6.6 million showcases the effectiveness of Cognyte's financial model and its capacity for profitable growth.

How is Cognyte leveraging AI in its operations?

Cognyte is utilizing advanced AI technologies to enhance its investigative analytics software, enabling clients to address complex security challenges effectively.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 223

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 154

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 122

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub

Updated Category News Views 207

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 22

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era

Updated Category News Views 148

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Continue Reading
WeFetch AI: A New Era in Barcode Precision

Updated Category News Views 225

WeFetch AI: What's in a Name? Forget about GreenCore Solutions Corp. We're talking about WeFetch AI Corp. now. They've just changed their name, fulfilling a bureaucratic tick as of November 13, 2026. But it ain't just a name change; it's a whole new ballgame in AI-driven commerce. AI Shopping Without the Guesswork We've all been there. You think you've ordered that...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 155

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 150

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Gaine Expands Healthcare Data Solutions Ahead of HLTH 2026

Updated Category News Views 233

Ever felt like healthcare systems are still stuck in a bygone era, struggling with data flinging through the void? Well, Gaine Technology is throwing down its gauntlet to change that narrative. Successful in pharmaceuticals and life sciences, they're turbocharging their Consent and Preference Management solution across the vast, tangled web of healthcare markets just in...

Continue Reading
les" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles